{"denoms":[{"counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"34"}],"units":"Participants"}],"groups":[{"description":"Tecemotide (L-BLP25): After receiving single low dose cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide \\[L-BLP25\\]) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy was documented.\n\nSingle low dose cyclophosphamide: An intravenous (IV) infusion of 300 milligram per square meter (mg/m\\^2) (to a maximum 600 mg) of cyclophosphamide was given 3 days before the first vaccine treatment.","id":"BG000","title":"Tecemotide (L-BLP25) Plus Single Low Dose Cyclophosphamide"},{"description":"Tecemotide (L-BLP25): After receiving multiple low dose cyclophosphamide, participants received 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide \\[L-BLP25\\]) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy was documented.\n\nMultiple low dose cyclophosphamide: An IV infusion of 300 mg/m\\^2 (to a maximum 600 mg) of cyclophosphamide was given 3 days before the first vaccine treatment plus an IV dose of cyclophosphamide (300 mg/m\\^2, to a maximum of 600 mg) 3 days prior to the tecemotide(LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week-14 up to a maximum treatment period of 2 years.","id":"BG001","title":"Tecemotide (L-BLP25) Plus Multiple Low Dose Cyclophosphamide"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.26","value":"62.5"},{"groupId":"BG001","spread":"9.36","value":"63.9"},{"groupId":"BG002","spread":"8.28","value":"63.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"15"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Safety analysis set included all the randomized participants who received at least 1 dose of trial treatment."}